- Home
- AVBP
as 04-17-2025 4:00pm EST
Stocks
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | NEWTOWN SQUARE |
| Market Cap: | 617.4M | IPO Year: | 2024 |
| Target Price: | $39.00 | AVG Volume (30 days): | 267.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.56 | EPS Growth: | N/A |
| 52 Week Low/High: | $14.35 - $36.37 | Next Earning Date: | 05-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 63.13% | Revenue Growth (next year): | N/A |
Latest ARRIVENT BIOPHARMA INC News
AVBP Breaking Stock News: Dive into AVBP Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
B. Riley Initiates ArriVent BioPharma at Buy With $37 Price Target
Insider Monkey
a month ago
ArriVent BioPharma (AVBP): Among the Best Short Squeeze Stocks to Buy According to Analysts
MT Newswires
a month ago
Guggenheim Initiates ArriVent BioPharma at Buy With $45 Price Target
GlobeNewswire
2 months ago
ArriVent BioPharma Reports Full Year 2024 Financial Results
TipRanks
3 months ago
ArriVent Biopharma price target raised to $39 from $36 at H.C. Wainwright
BioPharma Dive
3 months ago
Intellia makes progress on HAE study; 2 more China drug deals
MT Newswires
3 months ago
ArriVent BioPharma Enters Licensing Deal With Lepu Biopharma for Gastrointestinal Cancer Drug
GlobeNewswire
3 months ago
ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers
Compare AVBP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AVBP ARRIVENT BIOPHARMA INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.